- Why Research
- Our Impact
- Get Involved
- About BCRF
- Research is the reason
- Contact Us
You are here
A new type of drug is now approved for certain patients with metastatic breast cancer. Olaparib (Lynparza®) belongs to a class of drugs called PARP inhibitors.
Dr. Angela Hartley Brodie, Professor Emeritus in the Department of Pharmacology at the University of Maryland School of Medicine passed away from complications of Parkinson's Disease on June 7. She was 82.
Women diagnosed with larger tumors, typically stage II- III, may receive chemotherapy prior to surgery – called neoadjuvant therapy–to reduce the size of the tumor, which can allow for less extensive and breast conserving surgery.
Post mastectomy radiation therapy (PMRT) is commonly recommended for women with stage I-III breast cancer to prevent local recurrence.
CDK4/6 inhibitors are a new class of drugs that have shown promise in the treatment of advanced ER- positive breast cancer. Cyclin dependent kinases (CDK) regulate the process of cell division, required for growth.
March 14, 2017 – The Jayne Koskinas Ted Giovanis (JKTG) Foundation for Health and Policy and the Breast Cancer Research Foundation (BCRF) are jointly funding three multi-institutional collaborations with projects that have the potential to substantially advance understanding of cancer biology or
New Drug Combination Significantly Delays Tumor Progression in Some Forms of Metastatic Breast Cancer
Anti-estrogen therapies, such as tamoxifen and aromatase inhibitors, are standard therapy for breast cancers that depend on estrogen for growth – known as estrogen receptor-positive (ER+).
While much progress has been made in the treatment of breast cancer over the last 25 years, much work remains. New treatments are urgently needed for patients with metastatic breast cancer, triple-negative breast cancer and breast cancers that do not respond to currently available treatments, or